242 related articles for article (PubMed ID: 22267935)
1. Pharmacokinetics and pharmacodynamics of insulin analogs in special populations with type 2 diabetes mellitus.
Morello CM
Int J Gen Med; 2011; 4():827-35. PubMed ID: 22267935
[TBL] [Abstract][Full Text] [Related]
2. Insulin analogs in the treatment of type II diabetes and future perspectives.
Sebastian SA; Co EL; Mehendale M; Hameed M
Dis Mon; 2023 Mar; 69(3):101417. PubMed ID: 35487767
[TBL] [Abstract][Full Text] [Related]
3. Understanding how pharmacokinetic and pharmacodynamic differences of basal analog insulins influence clinical practice.
Goldman J; Kapitza C; Pettus J; Heise T
Curr Med Res Opin; 2017 Oct; 33(10):1821-1831. PubMed ID: 28537449
[TBL] [Abstract][Full Text] [Related]
4. Insulin analogs: Glimpse on contemporary facts and future prospective.
Sharma AK; Taneja G; Kumar A; Sahu M; Sharma G; Kumar A; Sardana S; Deep A
Life Sci; 2019 Feb; 219():90-99. PubMed ID: 30639280
[TBL] [Abstract][Full Text] [Related]
5. Beyond the era of NPH insulin--long-acting insulin analogs: chemistry, comparative pharmacology, and clinical application.
Owens DR; Bolli GB
Diabetes Technol Ther; 2008 Oct; 10(5):333-49. PubMed ID: 18715209
[TBL] [Abstract][Full Text] [Related]
6. Superiority of insulin analogues versus human insulin in the treatment of diabetes mellitus.
Rossetti P; Porcellati F; Fanelli CG; Perriello G; Torlone E; Bolli GB
Arch Physiol Biochem; 2008 Feb; 114(1):3-10. PubMed ID: 18465353
[TBL] [Abstract][Full Text] [Related]
7. Insulin analog preparations and their use in children and adolescents with type 1 diabetes mellitus.
Miles HL; Acerini CL
Paediatr Drugs; 2008; 10(3):163-76. PubMed ID: 18454569
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic and pharmacodynamic differences of new generation, longer-acting basal insulins: potential implications for clinical practice in type 2 diabetes.
Hompesch M; Patel DK; LaSalle JR; Bolli GB
Postgrad Med; 2019 Mar; 131(2):117-128. PubMed ID: 30691343
[TBL] [Abstract][Full Text] [Related]
9. A Review of Basal-Bolus Therapy Using Insulin Glargine and Insulin Lispro in the Management of Diabetes Mellitus.
Candido R; Wyne K; Romoli E
Diabetes Ther; 2018 Jun; 9(3):927-949. PubMed ID: 29654514
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of insulin lispro protamine suspension as basal supplementation in patients with type 2 diabetes.
Giugliano D; Esposito K
Ther Adv Endocrinol Metab; 2012 Jun; 3(3):99-108. PubMed ID: 23148201
[TBL] [Abstract][Full Text] [Related]
11. Treatment of type 1 and type 2 diabetes mellitus with insulin detemir, a long-acting insulin analog.
Young JR; McAdam-Marx C
Clin Med Insights Endocrinol Diabetes; 2010; 3():65-80. PubMed ID: 22879788
[TBL] [Abstract][Full Text] [Related]
12. Evolution of insulin development: focus on key parameters.
Tibaldi JM
Adv Ther; 2012 Jul; 29(7):590-619. PubMed ID: 22843207
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the effect of insulin glulisine to insulin aspart on breakfast postprandial blood glucose levels in children with type 1 diabetes mellitus on multiple daily injections.
Cemeroglu AP; Kleis L; Wood A; Parkes C; Wood MA; Davis AT
Endocr Pract; 2013; 19(4):614-9. PubMed ID: 23425652
[TBL] [Abstract][Full Text] [Related]
14. The continuing quest for better subcutaneously administered prandial insulins: a review of recent developments and potential clinical implications.
Owens DR; Bolli GB
Diabetes Obes Metab; 2020 May; 22(5):743-754. PubMed ID: 31930670
[TBL] [Abstract][Full Text] [Related]
15. Detemir as a once-daily basal insulin in type 2 diabetes.
Nelson SE
Clin Pharmacol; 2011; 3():27-37. PubMed ID: 22287854
[TBL] [Abstract][Full Text] [Related]
16. Subcutaneous insulin: pharmacokinetic variability and glycemic variability.
Guerci B; Sauvanet JP
Diabetes Metab; 2005 Sep; 31(4 Pt 2):4S7-4S24. PubMed ID: 16389894
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Rapid-Acting Insulin Analogs in Special Populations with Type 1 Diabetes or Gestational Diabetes: Systematic Review and Meta-Analysis.
Nørgaard K; Sukumar N; Rafnsson SB; Saravanan P
Diabetes Ther; 2018 Jun; 9(3):891-917. PubMed ID: 29623593
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and pharmacodynamics of basal insulins.
Porcellati F; Bolli GB; Fanelli CG
Diabetes Technol Ther; 2011 Jun; 13 Suppl 1():S15-24. PubMed ID: 21668333
[TBL] [Abstract][Full Text] [Related]
19. Use of a novel double-antibody technique to describe the pharmacokinetics of rapid-acting insulin analogs.
Lindström T; Hedman CA; Arnqvist HJ
Diabetes Care; 2002 Jun; 25(6):1049-54. PubMed ID: 12032113
[TBL] [Abstract][Full Text] [Related]
20. Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison.
Ilag LL; Kerr L; Malone JK; Tan MH
Clin Ther; 2007; 29 Spec No():1254-70. PubMed ID: 18046926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
